The Peptide NewsroomPeptide research, industry and supply-chain headlines

Yak Collagen Peptides Blocked MMP-1 in Lab Tests, But the Lifespan Data Is All Worms

Topic card: collagen peptides

Three peptides derived from yak bone collagen inhibited the enzyme MMP-1 and extended the lifespan of nematodes, according to a study published as an early-access, peer-reviewed article in npj Science of Food. The work pairs a machine-learning screen of collagen sequences with wet-lab testing of the three best candidates.

The species matters here and it matters early. Every biological result in this paper comes from an enzyme assay, computational modeling, or Caenorhabditis elegans, a millimeter-long worm. No human participants were involved, and the authors are explicit that the findings do not demonstrate clinical anti-aging benefits, safety or efficacy in people.

What MMP-1 actually is

MMP-1 is a matrix metalloproteinase, an enzyme that breaks down collagen in connective tissue. Inhibiting it is a long-standing target in skin and aging research, which is why a collagen-derived peptide that slows it down is interesting rather than routine.

How the peptides were found

The team built a screening model called AgeAttnMLP on top of the ESM-2 protein language model to rank candidate bioactive peptides from yak collagen sequences. It reached an AUC of 0.891 under conventional five-fold cross-validation and 0.879 in a stricter cluster-aware grouped evaluation, the second number being the more honest one and the one most papers in this genre quietly omit.

From there, Alcalase-guided in silico hydrolysis narrowed the field to three sequences for bench testing: TGPPGPSGI, GEPGAPGE and GPSGEPGTA.

Key results

GEPGAPGE was the strongest MMP-1 inhibitor of the three, with an IC50 of 126 micrograms per milliliter. All three extended worm lifespan, with the largest effect seen for GPSGEPGTA at 7.5 milligrams per milliliter.

Molecular-dynamics simulations and MM-PBSA binding-energy analysis suggested the peptides destabilize a beta-sheet spanning residues 76 to 78 near the catalytic region of MMP-1, potentially disrupting substrate recognition. That is a computational interpretation, and the reported findings include no direct experimental confirmation of the mechanism.

Limitations

The study links two measured outcomes without connecting them: it does not establish that MMP-1 inhibition caused the longevity effect in worms. Conclusions are explicitly limited to the tested compounds, concentrations and experimental systems.

Bottom line

As a demonstration that a slaughterhouse byproduct can yield peptides with measurable enzyme activity, this is a tidy piece of work. As evidence for anything a person could swallow, it has not started.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: collagen

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

Jessica Pegula Names Collagen Peptides a Daily Staple, But the Evidence Is Hers Alone

Tennis player Jessica Pegula named collagen peptides among her six daily must-haves in a Page Six Style interview, alongside sunscreen and a recovery tracker. She also has a partnership with the collagen brand she named, and the piece cites no study or outcome figure at all.

Collagen Peptides May Help Tendons Adapt, But Whey Still Wins on Muscle Size

A ZME Science feature weighs the fitness industry's peptide claims against the trial data, finding whey ahead of collagen on muscle size but a real signal for collagen on tendon adaptation. Much of the supporting evidence is rated low certainty, and injury prevention remains unestablished.

Darling Ingredients Launches a Cognitive Collagen Peptide Before Its Human Trials Begin

Darling Ingredients and Rousselot have introduced Nextida NxCogni, a collagen peptide ingredient the company says is formulated to support clarity and cognitive resilience. The first human study is not scheduled until December 2026, two months after the ingredient's trade show debut.